Renaissance Sterile

Renaissance Sterile specializes in pharmaceutical contract development and manufacturing, focusing on nasal spray formulations and sterile injectables, providing comprehensive solutions from R&D to commercialization. Founded in 2016 and headquartered in Newton, US, Renaissance Sterile provides contract development and manufacturing services to the pharmaceutical sector. The company was formed through a combination of expertise and strategic focus on drug delivery systems. It has made one notable deal, with Roundtable Healthcare Partners acquiring Renaissance Acquisition Holdings, LLC in December 2010, although financial terms were not disclosed.

Renaissance Lakewood LLC specializes in contract development and manufacturing services for the pharmaceutical industry, particularly focusing on nasal spray formulations and sterile injectable dosage forms. Their core offerings include nasal spray manufacturing, testing, aseptic filling, and comprehensive research and development services. With nearly two decades of expertise in nasal spray technology, Renaissance provides a "one-stop-shop" solution that encompasses formulation, development, testing, and commercialization, catering to the needs of both clinical and commercial volumes. Their products are primarily utilized by pharmaceutical companies looking to bring innovative drug delivery systems to market, addressing a wide range of therapeutic areas for patients worldwide.

The company's geographical market extends beyond the United States, serving global clients with a need for high-quality pharmaceutical products that meet stringent regulatory standards. Renaissance Lakewood LLC generates revenue through a business-to-business model, providing contract manufacturing services to various pharmaceutical companies. Transactions typically occur through project-based agreements, where clients engage Renaissance for specific services ranging from product development to full-scale manufacturing. The company utilizes a tiered pricing structure based on the complexity and scale of services provided, which may include one-time fees for development or ongoing fees for long-term manufacturing contracts.

Their flagship products, such as unit-dose and bi-dose nasal sprays, play a crucial role in their revenue streams, as they cater to the increasing demand for innovative drug delivery methods in the pharmaceutical market. By maintaining rigorous compliance with current Good Manufacturing Practices (cGMP), Renaissance ensures the quality and reliability of its offerings, fostering long-term partnerships with clients in need of expert manufacturing capabilities. Renaissance Sterile's strategy for future growth includes the introduction of new nasal spray formulations, aimed at meeting evolving market demands, with anticipated launches in the next 12 to 18 months. The company is also looking to expand its reach into international markets, specifically targeting Europe and Asia by 2025.

Recent funding from Roundtable Healthcare Partners will be utilized to support these initiatives, including the enhancement of production capabilities and the development of innovative products to fulfill prospective client needs.